Enliven Therapeutics Inc’s recently made public that its CHIEF FINANCIAL OFFICER Hohl Benjamin unloaded Company’s shares for reported $69321.0 on Mar 27 ’25. In the deal valued at $21.33 per share,3,250 shares were sold. As a result of this transaction, Hohl Benjamin now holds 23,000 shares worth roughly $0.45 million.
Then, Hohl Benjamin bought 4,250 shares, generating $87,465 in total proceeds.
Before that, Hohl Benjamin sold 1,000 shares. Enliven Therapeutics Inc shares valued at $22,504 were divested by the CHIEF FINANCIAL OFFICER at a price of $22.50 per share. As a result of the transaction, Hohl Benjamin now holds 23,000 shares, worth roughly $0.45 million.
BTIG Research initiated its Enliven Therapeutics Inc [ELVN] rating to a Buy in a research note published on December 13, 2024; the price target was $42. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating. Robert W. Baird began covering ELVN with “an Outperform” recommendation on June 11, 2024. Mizuho started covering the stock on April 09, 2024. It rated ELVN as “a Buy”.
Price Performance Review of ELVN
On Monday, Enliven Therapeutics Inc [NASDAQ:ELVN] saw its stock fall -6.60% to $19.68. Over the last five days, the stock has lost -12.38%. Enliven Therapeutics Inc shares have fallen nearly -12.53% since the year began. Nevertheless, the stocks have risen 5.64% over the past one year. While a 52-week high of $30.03 was reached on 01/03/25, a 52-week low of $15.96 was recorded on 03/04/25. SMA at 50 days reached $21.24, while 200 days put it at $23.47.
Levels Of Support And Resistance For ELVN Stock
The 24-hour chart illustrates a support level at 19.05, which if violated will result in even more drops to 18.43. On the upside, there is a resistance level at 20.73. A further resistance level may holdings at 21.79. The Relative Strength Index (RSI) on the 14-day chart is 42.20, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.17, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.77%. Stochastics %K at 39.49% indicates the stock is a holding.
How much short interest is there in Enliven Therapeutics Inc?
A steep rise in short interest was recorded in Enliven Therapeutics Inc stocks on 2025-03-14, dropping by -0.11 million shares to a total of 7.34 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 7.44 million shares. There was a decline of -1.46%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 29, 2023 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $27 price target.
